Prevalence of Anti-erythropoietin Anti-Body in Prevalent Hemodialysis Patients Receiving Erythropoietin Hormone

Abstract

hronic kidney disease (CKD) is considered a public health problem worldwide with high incidence and prevalence rates. In end stage renal disease (ESRD), renal function must be replaced by dialysis or renal transplantation. (Murphy et al., 2016). Dialysis therapy ameliorates many of clinical manifestations of end-stage renal disease (ESRD) and postpones imminent death. Mortality rates are high among dialysis patients and dialysis outcomes vary across facilities and countries (Port, 2014). Recombinant form of Epo is a sialo glycoprotein hormone that appears to be immunologically and biologically equivalent to the endogenous compound enhancing erythropoiesis (Urra et al., 1997). The development of neutralizing anti-Epo antibodies was found to be associated with pure red cell aplasia (PRCA). These antibodies probably cross react with the patient’s endogenous Epo and lead to anemia that can be more severe than even before the onset of Epo therapy (Miyazak et al., 2007).